# Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Source: https://onco.cc/trials/nct04060394/  
OnCo record `nct04060394` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Afuresertib and Lapiteronel run by Laekna Limited, completed.

## Summary

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC is a phase 1/2 interventional study registered as NCT04060394 by Laekna Limited, with 49 participants enrolled, started 2019-09-13, primary completion reached 2023-12-27. Conditions recorded: Metastatic Castration-resistant Prostate Cancer. Interventions recorded: Phase I and Phase II: LAE001/prednisone + afuresertib.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04060394
- Phase: 1/2
- Setting: A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
- Sponsor: Laekna Limited
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT04060394: https://clinicaltrials.gov/study/NCT04060394

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/)
- drugs: [Afuresertib](https://onco.cc/drugs/afuresertib/), [Lapiteronel](https://onco.cc/drugs/lapiteronel/)
- companies: [Laekna Therapeutics](https://onco.cc/companies/laekna-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct04060394.json